Patent application number | Description | Published |
20080213296 | Immunogen - The present invention relates, in general, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same. | 09-04-2008 |
20080254061 | Mycobacteria Expressing Hiv-1 and Malaria Antigens - Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are | 10-16-2008 |
20090136522 | Multivalent Immunogen - The present invention relates, in general, to HIV and, in particular, to immunogens that present epitopes located in the membrane external proximal region (MPER) of HIV-I envelope gp41 in multivalent form and to methods of using same. | 05-28-2009 |
20090162384 | Consensus/ancestral immunogens - The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens. | 06-25-2009 |
20090198042 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 08-06-2009 |
20090202651 | Antigen specific fluorescent nanoparticles - The present invention relates, in general, to nanoparticles and, in particular, to nanoparticles coated with, for example, peptides, proteins, and/or carbohydrates, and to methods of producing and using same. The invention further relates to kits comprising the coated nanoparticles. | 08-13-2009 |
20090311289 | VACCINE - The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same. | 12-17-2009 |
20090317419 | Tetramers - The present invention relates, in general to human immunodeficiency virus (HIV), and, in particular, to B cell tetramers and to methods of using same for diagnosis, disease monitoring and vaccine development. | 12-24-2009 |
20090324631 | Polyvalent Vaccine - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-31-2009 |
20100028415 | Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 02-04-2010 |
20100047331 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 02-25-2010 |
20100104596 | ACUTTE TRANSMITTED HIV ENVELOPE SIGNATURES - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a method of inducing an immune response to HIV in a patient and to immunogens suitable for use in such a method. The invention also relates to diagnostic test kits and methods of using same. | 04-29-2010 |
20100221700 | METHOD OF MONITORING HIV INFECTION - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a method of monitoring the intensity of HIV infection and predicting the time to progression to acquired immunodeficiency syndrome (AIDS). | 09-02-2010 |
20100285106 | MULTICOMPONENT VACCINE - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a multicomponent vaccine and method of using same to protect against HTV-I infection. | 11-11-2010 |
20100303848 | VACCINATION METHOD - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to methods of effecting local and systemic immunization against HIV while protecting cells (e.g., mucosal dendritic and epithelial cells) from viral challenge. The invention further relates to compounds (e.g., nucleic acids encoding polypeptides that can elicit an immune response and/or protect cells against viral challenge) and compositions suitable for use in such methods. | 12-02-2010 |
20100316672 | VACCINE - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to HIV-I envelope (Env) immunogens. | 12-16-2010 |
20110150915 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 06-23-2011 |
20110159037 | METHODS OF TREATING AND PROTECTING AGAINST HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies against HIV, to a method of inducing antibodies protective against HIV and to compounds and compositions suitable for use in such methods. | 06-30-2011 |
20110236373 | Method of detecting antibodies and antibody-hiv virion complexes - The present invention relates, in general, to HIV and, in particular to a method of detecting anti-HIV antibodies and antibody-HIV virion complexes. | 09-29-2011 |
20110262526 | METHOD OF INDUCING AN ANTI-VIRAL IMMUNE RESPONSE - The present invention relates to a method of inducing an anti-viral immune response. The method comprises administering to a patient in need thereof an antigen that induces the production of antibodies that, upon binding to a cell surface target, result in the production of chemokines that inhibit viral infection. | 10-27-2011 |
20110301328 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 12-08-2011 |
20110305700 | Anti-lipid antibodies - The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-1 infection using anti-lipid (e.g. antiphospholipid) antibodies. | 12-15-2011 |
20110318360 | ANTI-LIPID ANTIBODIES - The present invention relates, in general, to anti-lipid antibodies and, in particular, to methods of inhibiting HIV-I infection using anti-lipid (e.g. anti-phospholipid) antibodies. | 12-29-2011 |
20120070488 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 03-22-2012 |
20120087938 | Consensus/ancestral immunogens - The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens. | 04-12-2012 |
20120102582 | MOUSE MODELS - The present invention relates, in general, to animal models suitable for testing candidate immunogens and, in particular, to knock-in mice expressing heavy and light chains of membrane proximal external region (MPER) HIV-I broadly neutralizing antibodies and to methods of screening candidate immunogens using same. | 04-26-2012 |
20120121631 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 05-17-2012 |
20120128758 | FORMULATION FOR INDUCING BROADLY REACTIVE NEUTRALIZING ANTI-HIV ANTIBODIES - The present invention relates in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies, and, in particular, to a formulation comprising Toll Like Receptor (TLR) agonists with HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such formulations. | 05-24-2012 |
20120177721 | FORMULATION - The present invention relates, in general, to a formulation suitable for use in inducing anti-HIV-1 antibodies and, in particular, to a formulation comprising a prehairpin intermediate form of HIV-1 envelope gp41 linked to a liposome. The invention also relates to methods of inducing broadly neutralizing anti-HIV-1 antibodies using such a formulation. | 07-12-2012 |
20120183597 | Method of inducing neutralizing antibodies to human immunodeficiency virus - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 07-19-2012 |
20120231028 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 09-13-2012 |
20120269821 | HIV-1 ANTIBODIES - The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER). | 10-25-2012 |
20120321699 | METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES - The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method. | 12-20-2012 |
20130029424 | METHOD FOR THE GENERATION OF MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS - The present invention relates, in general, to human B cells, and, in particular to a method of immortalizing and cloning human B cells and to monoclonal antibodies derived therefrom. The invention further relates to methods of using the monoclonal antibodies for therapeutic and diagnostic purposes. | 01-31-2013 |
20130164316 | GENETIC SIGNATURES IN HIV-1 SUBTYPE C ENVELOPE GLYCOPROTEINS - The present invention relates, in general, to HIV-1 and, in particular, to immunogens that elicit broadly neutralizing antibodies against HIV-1 subtype C envelope glycoproteins, and compositions comprising same. The invention further relates to methods of inducing the production of such antibodies in a subject. | 06-27-2013 |
20130177583 | MOLECULAR CLONE OF HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection. | 07-11-2013 |
20130217002 | HIV-1 IGG3 RESPONSE IN ACUTE HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to methods of detecting incident HIV-1 infection. | 08-22-2013 |
20130243850 | ADJUVANT - The present invention relates, in general, to human immunodeficiency vims (HIV- | 09-19-2013 |
20130273103 | POLYVALENT IMMUNOGEN - The present invention relates, in general, to HIV-1 and, in particular, to polyvalent immunogens suitable for use in inducing an immune response to HIV-1 in a patient, and to methods of identifying such immunogens. The invention further relates to methods of inducing an anti-HIV-1 immune response using such immunogens. | 10-17-2013 |
20130323299 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 12-05-2013 |
20140023683 | IDENTIFICATION OF TRANSMITTED HEPATITIS C VIRUS (HCV) GENOMES BY SINGLE GENOME AMPLIFICATION - This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences. | 01-23-2014 |
20140205607 | FOCUSED EVOLUTION OF HIV-1 NEUTRALIZING ANTIBODIES REVEALED BY CRYSTAL STRUCTURES AND DEEP SEQUENCING - Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different antibodies to the same CD4-binding-site epitope. Antibody recognition was achieved through the evolution of complementary contact domains that were generated in diverse ways. Phylogenetic analysis of expressed heavy and light chains determined by deep sequencing revealed a common pathway of antibody heavy chain maturation confined to IGHV1-2*02 lineage that could pair with different light chains. The maturation pathway inferred by antibodyomics reveals that diverse antibodies evolve to a highly affinity-matured state to recognize an invariant viral structure, providing insight into the development and evolution of broadly neutralizing HIV-1 immunity. | 07-24-2014 |
20140248301 | METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES - The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method. | 09-04-2014 |
20140248311 | N-TERMINAL DELETED GP120 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 09-04-2014 |
20140302043 | BROADLY NEUTRALIZING HUMAN ANTIBODY THAT RECOGNIZES THE RECEPTOR-BINDING POCKET OF INFLUENZA HEMAGGLUTININ - The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection. | 10-09-2014 |
20140302062 | HERPES SIMPLEX VIRUS - The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies. | 10-09-2014 |
20140322262 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 10-30-2014 |
20140335126 | V1V2 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 11-13-2014 |
20140341949 | VACCINE - The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol. | 11-20-2014 |
20150050309 | VACCINE - The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same. | 02-19-2015 |